创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology ELISpot Platform: Unique Advantages of Leading Immune Response Analysis

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-25 15:12
  • Views:

(Summary description)Immune response analysis plays a pivotal role in the broad field of life science research. Especially in cancer immunotherapy, vaccine development and infectious disease research, accurate analysis of cytotoxic T-lymphocytes (CTLs) and their immune responses is crucial. With its advanced ELISpot platform, InnoModels Biotechnology provides researchers with a powerful and reliable experimental tool, and its unique advantages are well recognized in the industry.

InnoModels Biotechnology ELISpot Platform: Unique Advantages of Leading Immune Response Analysis

(Summary description)Immune response analysis plays a pivotal role in the broad field of life science research. Especially in cancer immunotherapy, vaccine development and infectious disease research, accurate analysis of cytotoxic T-lymphocytes (CTLs) and their immune responses is crucial. With its advanced ELISpot platform, InnoModels Biotechnology provides researchers with a powerful and reliable experimental tool, and its unique advantages are well recognized in the industry.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-25 15:12
  • Views:
Information

Immune response analysis plays a pivotal role in the broad field of life science research. Especially in cancer immunotherapy, vaccine development and infectious disease research, accurate analysis of cytotoxic T-lymphocytes (CTLs) and their immune responses is crucial. With its advanced ELISpot platform, InnoModels Biotechnology provides researchers with a powerful and reliable experimental tool, and its unique advantages are well recognized in the industry.
1. High sensitivity detection capability
InnoModels' ELISpot platform stands out for its high sensitivity. This platform is capable of accurately detecting and quantitatively analyzing proteins released by individual cells, including cytokines, antibodies, etc., thus enabling quantitative and qualitative analysis of the level of CTLs produced. This advantage is particularly important in tumor vaccine research and cancer immunotherapy, as it enables accurate assessment of the activity of CTLs and thus the effectiveness of immunotherapy.
2、Specific MHC antigen delivery activates CTLs
In immune response analysis, specific activation of CTLs is the key to assessing the effect of immunotherapy. InnoModels' ELISpot platform utilizes the specific MHC antigen presentation pathway to activate CTLs, ensuring that the activation of CTLs is dependent on the presence of appropriate MHC molecules. This specific activation avoids activating CTLs in the presence of MHC mismatches, thereby improving the accuracy and reliability of the experiment.
3. Versatility and Flexibility
InnoModels' ELISpot platform is versatile and flexible to meet different research needs. The platform supports a variety of CTLs stimulation methods, including the use of human or mouse peripheral blood mononuclear cells (PBMCs) or splenic immune cells for in vitro specific antigen presentation, as well as the analysis of peripheral blood or splenic cells after in vivo immunization of immunologically sound mice. In addition, the platform also focuses on CTL detection in TILs, providing researchers with a broader research space.

 


4. Wide range of application areas
InnoModels' ELISpot platform has a wide range of applications in immunology research, biomedical research and vaccine development. The platform is not only suitable for clinical cancer vaccine research, but also for in vitro research of tumor vaccines and immunomodulatory drugs. Its high sensitivity and specificity give it a unique advantage in discovering new biomarkers and evaluating vaccine efficacy.
5、Customer training and technical support
As a company focusing on customer satisfaction, InnoModels Biotechnology not only provides advanced ELISpot technology, but is also committed to providing comprehensive training and technical support to users. Through online training, seminars and a professional technical support team, InnoModels Biotechnology ensures that users are able to fully understand and properly apply ELISpot technology to maximize its benefits.
6. Continuous Innovation and Development
InnoModels Biotechnology continues to invest in research and development in the field of ELISpot technology, launching new products and technological innovations. Close collaboration with academic and industrial partners keeps InnoModels Biotechnology at the forefront of technology and meets the constant demand for efficient and reliable immunoassay tools in the research field.
In summary, the ELISpot platform of InnoModels Biotechnology plays an irreplaceable role in life science research with its unique advantages of high sensitivity, specific MHC antigen presentation and activation of CTLs, versatility, flexibility, wide range of applications, as well as customer training and technical support. It is believed that in the future, the ELISpot platform of InnoModels Biotechnology will continue to provide powerful and reliable experimental tools for researchers and help them make more breakthroughs in the field of life sciences.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司